Annovis Bio, a Phase 2 biotech developing therapies for neurodegenerative diseases, raised $12 million by offering 2 million shares at $6, the low end of the range of $6 to $8. The company raised $2 million more than expected by offering 40% more...read more
Annovis Bio, a Phase 2 biotech developing therapies for neurodegenerative diseases, announced terms for its IPO on Friday.
The Berwyn, PA-based company plans to raise $10 million by offering 1.4 million shares at a price range of $6 to $8. At the midpoint of ...read more
Annovis Bio, a clinical stage biotech developing therapies for neurodegenerative diseases, filed on Wednesday with the SEC to raise up to $12 million in an initial public offering. The Berwyn, PA-based company was founded in 2008 and it plans to list on the...read more
Nano-cap Alzheimer's biotech Annovis Bio prices up-sized IPO at $6 low end
Annovis Bio, a Phase 2 biotech developing therapies for neurodegenerative diseases, raised $12 million by offering 2 million shares at $6, the low end of the range of $6 to $8. The company raised $2 million more than expected by offering 40% more...read more
Neurodegenerative disease biotech Annovis Bio sets terms for $10 million IPO
Annovis Bio, a Phase 2 biotech developing therapies for neurodegenerative diseases, announced terms for its IPO on Friday. The Berwyn, PA-based company plans to raise $10 million by offering 1.4 million shares at a price range of $6 to $8. At the midpoint of ...read more
Neurodegenerative disease biotech Annovis Bio files for a $12 million IPO
Annovis Bio, a clinical stage biotech developing therapies for neurodegenerative diseases, filed on Wednesday with the SEC to raise up to $12 million in an initial public offering. The Berwyn, PA-based company was founded in 2008 and it plans to list on the...read more